The expedited DEA administrative hearing on broader marijuana rescheduling from Schedule I to III concluded by July 15, 2026, after partial rescheduling of FDA-approved products and state medical marijuana took effect in late April. President Trump’s December 2025 executive order directed the Justice Department and DEA to complete the process expeditiously, shifting focus from the original 2024 NPRM to an accelerated rulemaking track. Trader consensus on timelines centers on the remaining steps—administrative law judge recommendation, DEA and Attorney General review, and Federal Register publication—while accounting for potential procedural delays, participant challenges, or further legal review. Key upcoming catalysts include any final order issuance and confirmation of effective dates for comprehensive reclassification under the Controlled Substances Act.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated$795,662 Vol.
September 30
14%
December 31
27%
$795,662 Vol.
September 30
14%
December 31
27%
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Market Opened: Feb 7, 2026, 5:04 PM ET
Resolver
0x65070BE91...The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Resolver
0x65070BE91...The expedited DEA administrative hearing on broader marijuana rescheduling from Schedule I to III concluded by July 15, 2026, after partial rescheduling of FDA-approved products and state medical marijuana took effect in late April. President Trump’s December 2025 executive order directed the Justice Department and DEA to complete the process expeditiously, shifting focus from the original 2024 NPRM to an accelerated rulemaking track. Trader consensus on timelines centers on the remaining steps—administrative law judge recommendation, DEA and Attorney General review, and Federal Register publication—while accounting for potential procedural delays, participant challenges, or further legal review. Key upcoming catalysts include any final order issuance and confirmation of effective dates for comprehensive reclassification under the Controlled Substances Act.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated



Beware of external links.
Beware of external links.
Frequently Asked Questions